Cannabinoids exhibit immunosuppressive actions that include inhibition of interleukin-2 production in response to a variety of T cell activation stimuli. Traditionally, the effects of these compounds have been attributed to cannabinoid receptors CB1 and CB2, both of which are expressed in mouse splenocytes. Therefore, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorphenyl)-4-methyl-H-pyrazole-3 carboxyamidehydrochloride (SR141716A), a CB1 antagonist, and N- [(1S)-endo-1,3,3,-trimethyl-bicyclo[2,2,1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (SR144528), a CB2 antagonist, were used to investigate the role of cannabinoid receptors in the cannabinoid-induced inhibition of phorbol ester plus calcium ionophore (PMA/Io)-stimulated interleukin-2 production by mouse splenocytes. PMA/Io-stimulated interleukin-2 production was inhibited by cannabinol, cannabidiol, and both WIN 55212-2 stereoisomers with a rank order potency of R-(ϩ)- [2,3-dihydro-5-methyl-3-[(morpholinyl)
tion of PMA/Io-stimulated interleukin-2 was not attenuated by the presence of both SR144528 and SR141716A. Using pertussis toxin to address the role of G protein-coupled receptors in this response, it was determined that pertussis toxin treatment did not attenuate cannabinol-induced inhibition of PMA/Io-stimulated interleukin-2. With the demonstration that cannabinoid-induced inhibition of PMA/Iostimulated interleukin-2 was not mediated via CB1 or CB2, alternative targets of cannabinoids in T cells were examined. Specifically, it was demonstrated that cannabinoids elevated intracellular calcium concentration in resting splenocytes and that the cannabinol-induced elevation in intracellular calcium concentration was attenuated by treatment with both SR144528 and SR141716A. Interestingly, pretreatment of splenocytes with agents that elevate intracellular calcium concentration inhibited PMA/Io-stimulated interleukin-2 production, suggesting that an elevation in intracellular calcium concentration might be involved in the mechanism of interleukin-2 inhibition. These studies suggest that immune modulation produced by cannabinoids involves multiple mechanisms, which might be both cannabinoid receptordependent and -independent.
Cannabinoids are plant-derived molecules that produce a variety of biological effects of which the most extensively studied have been on the central nervous system and immune system. Specifically in the immune system, cannabinoids modulate innate and acquired (humoral, cell-mediated) immunity (for review, see Berdyshev, 2000) . With respect to acquired immunity, modulation of interleukin-2 production is one of the more sensitive targets of cannabinoids. It is interesting that cannabinoids either enhance or inhibit interleukin-2 secretion, depending on the experimental conditions, including age of the animals and magnitude of cellular activation (Nakano et al., 1992 (Nakano et al., , 1993 Jan and Kaminski, 2001) . Using an optimum stimulatory concentration of PMA/ Io, cannabinol treatment inhibited interleukin-2 protein secretion by splenic T cells (Condie et al., 1996) . This inhibition correlated with a decrease in expression of phosphorylated extracellular signal-regulated kinase mitogen-activated protein kinase (Faubert and Kaminski, 2000) . Furthermore, it was determined that cannabinol inhibited transcription factor binding to the proximal activator protein-1 and distal nuclear factor of activated T cells motifs in the interleukin-2 promoter (Condie et al., 1996; Faubert and Kaminski, 2000; Yea et al., 2000) , which might also contribute to the inhibition of interleukin-2. Thus, although the mechanism of cannabinoid-induced inhibition of interleukin-2 in PMA/Io-stimulated splenocyte is understood to occur via inhibition of transcriptional activation of interleukin-2 (Yea et al., 2000) , the upstream signals contributing to inhibition of transcription have not been completely elucidated. Likewise, the role of cannabinoid receptors in the inhibition of interleukin-2 by cannabinoid treatment has remained elusive.
The identification of cannabinoid receptors provided a putative mechanism for cannabinoid-mediated effects (Matsuda et al., 1990; Munro et al., 1993) . Cannabinoid receptors, both CB1 and CB2, belong to the G protein-coupled family of receptors and can couple negatively to adenylate cyclase (for review, see Matsuda, 1997) . In addition, both receptors have been shown to activate extracellular signal-regulated kinase mitogen-activated protein kinase in cannabinoid receptortransfected cell lines. The CB1 receptor has also been shown to couple negatively to N-and Q-type calcium channels and positively to inwardly rectifying and A-type potassium channels (for review, see Matsuda, 1997) . CB1 expression is highest in the CNS but has also been detected in several peripheral tissues (including most immune system cells), whereas CB2 expression is highest in cells of the immune system (Bouaboula et al., 1993; Galiegue et al., 1995; Schatz et al., 1997) . It is for that reason that many of these studies were conducted with cannabinol, a ligand that exhibits 10-fold greater affinity for the CB2 receptor compared with CB1 (Munro et al., 1993) .
Synthesis of cannabinoid receptor antagonists SR141716A and SR144528, which antagonize actions at CB1 and CB2, respectively (Rinaldi-Carmona et al., 1994; Rinaldi-Carmona et al., 1998) , allowed for the determination of cannabinoid receptor function for many of the effects of these compounds. This is particularly true for the CB1 receptor in that many of the cannabinoid-induced CNS effects were prevented by SR141716A treatment (for review, see Matsuda, 1997) . Furthermore, use of CB1 receptor knockout mice confirmed that the CB1 receptor mediated many of the CNS effects produced by cannabinoids (catalepsy, hypomotility, and hypothermia) (Ledent et al., 1999; Steiner et al., 1999; Zimmer et al., 1999) . CB1 is present in many immune cells at relatively low levels, and there are a few instances in which CB1 was determined to mediate immune system effects of cannabinoids (for review, see Berdyshev, 2000) . On the other hand, CB2 is believed not to play a role in the CNS effects of cannabinoids (Griffin et al., 1999; Buckley et al., 2000) , yet has been shown to be important for immune system effects, particularly for cannabinoid-induced inhibition of antigen processing and presentation in macrophages (McCoy et al., 1999; Buckley et al., 2000) . Therefore, the objective of these studies was to investigate the mechanism, including the role of CB1 and CB2, of cannabinoid-induced inhibition of interleukin-2 production in PMA/Io-stimulated mouse splenocytes.
Materials and Methods
Cannabinoid Compounds. SR144528, SR141716A, cannabidiol, and cannabinol were provided by the National Institute on Drug Abuse. WIN 55212-2 and WIN 55212-3 were purchased from SigmaAldrich (St. Louis, MO).
Animals. Pathogen-free female B6C3F1 mice, 6 weeks of age, were purchased from Charles River Laboratories, Inc. (Wilmington, MA). On arrival, mice were randomized, transferred to plastic cages containing sawdust bedding (5 animals/cage), and quarantined for 1 week. Mice were given food (Purina Certified Laboratory Chow) and water ad libitum. Mice were not used for experimentation until their body weight was 17 to 20 g. Animal holding rooms were maintained at 21-24°C and 40 to 60% relative humidity with a 12-h light/dark cycle.
Preparation of Lymphocyte Culture. Mice were sacrificed and spleens or thymi were aseptically removed. Single cell suspensions (5 ϫ 10 6 cells/ml) were prepared and cells were cultured in RPMI 1640 medium supplemented with 100 units penicillin/ml, 100 units of streptomycin/ml, 50 M 2-mercaptoethanol, and 2% bovine calf serum.
Interleukin-2 ELISA. Splenocytes were either treated with antagonist or vehicle for 30 min at 37°C, followed by cannabinoid agonist treatment for 30 min at 37°C. Alternatively, splenocytes were treated with ionomycin, A23187, or thapsigargin for 30 min at 37°C. The cells were then treated with 40 nM PMA/0.5 M ionomycin for 24 h in media containing 2% bovine calf serum in 48-well culture plates at 0.5 ml/well. Cells were harvested and supernatants were collected and assayed in triplicate for interleukin-2 using an ELISA. Briefly, 96-well plates were coated for 1 h at 37°C with a purified rat anti-mouse interleukin-2 antibody (BD PharMingen, San Diego, CA), followed by blocking with 3% bovine serum albumin in phosphate-buffered saline/Tween 20 for 30 min at 37°C. Supernatants from splenocytes were incubated for 1 h at 37°C, followed by addition of biotinylated anti-mouse interleukin-2 antibody (BD PharMingen) for 1 h at RT. Streptavidin peroxidase was then incubated for 1 h at RT. Finally, tetramethylbenzidine substrate and 6 N H 2 SO 4 were added for color development, and samples were read with an EL-808 plate reader (Bio-Tek Instruments, Winooski, VT) at 450 nm. Samples were quantified from a standard curve prepared with interleukin-2 standard (mouse recombinant interleukin-2; BD PharMingen).
cAMP Determinations. Splenocytes were suspended in 5 ml of 2% bovine calf serum and treated with Gey's solution (5 ml/spleen). The splenocytes were swirled on ice for 5 min to lyse the red blood cells, followed by two washes in 2% bovine calf serum. Splenocytes were resuspended in RPMI 1640 medium supplemented with 1 mg/ml fatty-acid poor bovine serum albumin (Calbiochem, La Jolla, CA). Cells in 1-ml aliquots of cells were treated in triplicate with cannabinoid agonist for 30 min at 37°C. The cells were then treated with 25 M forskolin (Sigma-Aldrich) for 15 min at 37°C. The extraction, release, and quantitation of cAMP from cells were performed using cAMP assay kits (Diagnostic Products, Los Angeles, CA). For pertussis toxin treatment, cells were either treated with pertussis toxin (100 ng/ml, Sigma-Aldrich) or not treated for 24 h before subsequent agonist treatment.
Calcium Determination. Splenocytes were treated with Gey's solution to lyse the red blood cells. Cells were then washed twice in Ca 2ϩ -KREB buffer (129 mM NaCl, 5 mM KCl, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 1 mM CaCl 2 , 5 mM NaHCO 3 , 10 mM HEPES, 2.8 mM glucose, and 0.2% bovine serum albumin). Intracellular calcium concentration was determined by measuring the fluorescence of fura-2 dye, which is dually excited at 340 and 380 nm. Fura-2/AM dye (1 M; Molecular Probes, Eugene, OR) was added to the cells and incubated for 30 min at RT in the dark. Cells were harvested, washed three times with Ca 2ϩ -KREB buffer to remove extracellular fura-2 dye, and readjusted to 5 ϫ 10 6 cells/ml in Ca 2ϩ -KREB buffer. Cells were stored at RT in the dark until used. Cells were placed in a 3-ml quartz cuvette with constant stirring. Calcium determinations were performed at RT with a Spex 1681 0.22 spectrometer with dual excitation at 340 and 380 nm and emission at 510 nm (all slit widths were 1 mm). Intracellular calcium concentration calculations were based on maximum and minimum calcium values, as assessed with use of 0.1% Triton X and 250 mM EGTA, respectively. The dissociation constant for the Fura-2-calcium complex was 1.45 ϫ 10 Ϫ7 . For studies conducted in the absence of extracellular calcium, the KREB buffer was prepared as above without CaCl 2 and supplemented with 0.02 mM EGTA.
Statistical Analysis. The mean Ϯ S.E. was determined by a parametric analysis of variance for each treatment group. When significant differences were detected, treatment groups were compared with the appropriate control with the Dunnett's two-tailed t test (Dunnett, 1955) .
Results

Effect of Cannabinoid Receptor Antagonists on
Cannabinol-Induced Inhibition of PMA/Io-Stimulated Interleukin-2 Production. Previous work from this laboratory has established that cannabinoids inhibited PMA/Iostimulated interleukin-2 production by splenocytes, thymocytes, and EL-4 T cells under optimum activating conditions (Condie et al., 1996; Herring and Kaminski, 1999; Yea et al., 2000) . Thus, a characterization of the putative involvement of the cannabinoid receptors in cannabinoid-mediated inhibition of interleukin-2 production using splenocytes was conducted. It is notable that splenocytes express mRNA for both cannabinoid receptors (Schatz et al., 1997) ; thus; the CB1 and CB2 receptor antagonists were used in combination in these studies. As presented in Fig. 1 , interleukin-2 was readily induced by PMA/Io treatment and was inhibited by cannabinol (1-20 M) in a concentration-dependent manner. These studies were conducted with micromolar concentrations of cannabinoid compounds because it has been previously demonstrated that these concentrations are required in vitro due to both the lipophilicity of the cannabinoids and the serum concentration dependence for many of the cannabinoid effects (Faubert and Kaminski, 2000) . Pretreatment of splenocytes with a combination of antagonists (0.5 M/0.5 M, 2.5 M/2.5 M, and 5 M/5 M SR144528/SR141716A) did not significantly attenuate the cannabinol-mediated inhibition of interleukin-2 production at any cannabinol concentration tested. The antagonists alone did not significantly affect the levels of PMA/Io-stimulated interleukin-2 production at concentrations up to 0.5 M/0.5 M SR144528/ SR141716A. However, it is notable that at higher concentrations, including 2.5 M/2.5 M and 5 M/5 M SR144528/ SR141716A, the antagonist alone inhibited PMA/Io-induced interleukin-2 production by at least 30% compared with the vehicle controls. (Fig. 1, inset) . In other experiments, SR144528/SR141716A at higher concentrations (2.5 M/2.5 M and 5 M/5 M) produced an even greater decrease in interleukin-2 production, indicating that cells cultured for extended periods (24 h) in the presence of these antagonists were functionally affected by both of these agents. No evidence of inverse agonist activity was observed with either antagonist. The estimated IC 50 values for cannabinol were 15.4 M in the absence of antagonists and 13.3 M, 18.1 M, and 16.8 M in the presence of 0.5 M/0.5 M, 2.5 M/2.5 M, and 5 M/5 M SR144258/SR141716A, respectively.
Effect of Pertussis Toxin on Cannabinol-Induced Inhibition of PMA/Io-Stimulated Interleukin-2 Production. Due to the inability of the cannabinoid receptor antagonists to attenuate the cannabinol-induced inhibition of interleukin-2 production, pertussis toxin was used to examine the potential role of G␣ i /G␣ o protein involvement in this effect. Pertussis toxin (100 ng/ml) pretreatment for 24 h resulted in an increase (29.0%) in forskolin-stimulated cAMP production in splenocytes, which was statistically different from forskolin-stimulated splenocytes in the absence of pertussis toxin (data not shown). However, pertussis toxin pretreatment (10 and 100 ng/ml) did not attenuate the cannabinol-induced inhibition of PMA/Io-stimulated interleukin-2 production (Fig. 2) . The estimated IC 50 values for interleu- Fig. 1 . Effect of cannabinoid receptor antagonists on cannabinol (CBN)-induced inhibition of PMA/Io-stimulated interleukin-2 production. Splenocytes (5 ϫ 10 6 cells/ml) were treated with both SR141716A and SR144528 (SR) or 0.1% dimethyl sulfoxide (DMSO) vehicle (VH) for 30 min followed by cannabinol treatment for 30 min. Cells were stimulated with 40 nM PMA/0.5 M ionomycin for 24 h. The supernatants were harvested, and interleukin-2 production was measured by ELISA analysis. Cellular viability was Ն80% for all treatment groups as assessed by trypan blue exclusion. ‫,ء‬ p Ͻ 0.05 compared with VH group, ‫,ءء‬ p Ͻ 0.05 compared with the SR 0.5 M/0.5 M ϩ VH group; ‡, p Ͻ 0.05 compared with the SR 2.5 M/2.5 M ϩ VH group; #, p Ͻ 0.05 compared with the 5 M/5 M ϩ VH group. Results are representative of four separate experiments with three replicates per treatment group.
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at ASPET Journals on July 12, 2017 jpet.aspetjournals.org kin-2 inhibition by cannabinol were 16.3 M in the absence of pertussis toxin and 27.7 and 17.9 M in the presence of 10 and 100 ng/ml pertussis toxin, respectively. Pertussis toxin did not significantly modulate interleukin-2, with the exception that there was a modest but consistent increase in basal interleukin-2 secreted from the cells that were treated with 100 ng/ml pertussis toxin (approximately 10 -15 units/ml; Fig. 2, inset) .
Effect of Cannabinoid Receptor Antagonists on WINInduced Inhibition of PMA/Io-Stimulated Interleukin-2 Production. Another characteristic of a receptor-dependent mechanism is differential effects with stereoisomers. One such cannabinoid stereoisomer pair is the synthetic compounds WIN 55212-2 and WIN 55212-3. Both WIN 55212-2 ("active" isomer) and WIN 55212-3 ("inactive" isomer) inhibited PMA/Io-induced interleukin-2 production in a concentration-dependent manner; however, WIN 55212-2 demonstrated robust, and consistently greater, inhibition than observed with WIN 55212-3 (Fig. 3, A and B). The IC 50 values for WIN-induced inhibition of interleukin-2 were 3.3 M for WIN 55212-2 and 14.8 M for WIN 55212-3. Interestingly, WIN 55212-3 inhibited interleukin-2 as robustly as cannabinol, a ligand that exhibits selectivity for the CB2 receptor. Furthermore, the antagonists (0.5 M/0.5 M, 2.5 M/2.5 M, or 5 M/5 M SR144528/SR141716A) did not attenuate the inhibition of interleukin-2 by either WIN isomer (Fig. 3, A and B) . In the presence of SR141716A/SR144528, the IC 50 values were as follows: 3.9, 5.2, and 4.1 M for WIN 55212-2 in the presence of 0.5 M/0.5 M, 2.5 M/2.5 M, or 5 M/5 M SR144528/SR141716A, respectively; 14.9, 15.1, and 12.2 M for WIN 55212-3 in the presence of 0.5 M/0.5 M, 2.5 M/2.5 M, or 5 M/5 M SR144528/SR141716A, respectively.
Effect of Cannabinoid Receptor Antagonists on Cannabidiol-Induced Inhibition of PMA/Io-Stimulated Interleukin-2 Production. In light of the above-mentioned results, cannabidiol, another plant-derived cannabinoid was used to assess the role of cannabinoid receptors in cannabinoid-induced interleukin-2 inhibition. Cannabidiol was previously determined to exhibit low affinity for the CB2 receptor in HL-60 cells (Munro et al., 1993) and did not inhibit forskolin-stimulated cAMP production in CB1-transfected Chinese hamster ovary cells (Matsuda et al., 1990) . Collectively, these previous studies indicate that cannabidiol exhibits low affinity for both CB1 and CB2. In the present study, we show that in splenocytes, cannabidiol (1-20 M) robustly inhibited PMA/Io-stimulated interleukin-2 production with an IC 50 value of 4.1 M, and this inhibition was not attenuated by 0.5 M/0.5 M or 5 M/5 M SR144528/ SR141716A (Fig. 4) . The IC 50 values for cannabidiol-induced inhibition in the presence of the antagonists were 2.9 and 2.4 M for 0.5 M/0.5 M and 5 M/5 M concentrations of the SR144582/SR141716A, respectively. It was notable that the magnitude of inhibition of interleukin-2 by cannabidiol was greater than that of cannabinol, in spite of the fact that cannabinol possesses greater CB1 and CB2 affinity.
Cannabinol Elevated Intracellular Calcium Concentration in Resting Splenocytes. With the demonstration that CB1 and CB2 were not involved in cannabinoid-induced inhibition of PMA/Io-stimulated interleukin-2, other potential T cell targets were examined. A major target of cannabinoids in T cells is nuclear factor of activated T cells (Faubert and Kaminski, 2000; Yea et al., 2000) , a critical transcription factor in the regulation of interleukin-2 that is tightly controlled by changes in [Ca 2ϩ ] i (reviewed in (Cantrell, 1996) . Therefore, generation of the calcium signal seemed a likely point of inhibition by cannabinoid compounds. However, these studies revealed that cannabinol treatment elevated [Ca 2ϩ ] i for at least 30 min in resting splenocytes (Fig. 5A) . Although this sustained elevation by cannabinol in [Ca 2ϩ ] i was consistent with other agents that increase [Ca 2ϩ ] i , such as ionomycin and thapsigargin, the shapes of the elevation as well as the overall magnitude of elevation in [Ca 2ϩ ] i were different for cannabinol versus ionomycin or thapsigargin (Fig. 5, B and C) . 6 cells/ml) were treated with 10 or 100 ng/ml pertussis toxin for 24 h. The cells were harvested, washed, and resuspended to a cell density of 5 ϫ 10 6 cells in 2% bovine calf serum. Cells were treated with either cannabinol or 0.1% ethanol vehicle (VH) for 30 min followed by 40 nM PMA/0.5 M ionomycin for 24 h. The supernatants were harvested, and interleukin-2 production was measured by ELISA analysis. Cellular viability was Ն80% for all treatment groups as assessed by trypan blue exclusion. ‫,ء‬ p Ͻ 0.05 compared with the VH group; ‫,ءء‬ p Ͻ 0.05 compared with the pertussis toxin 10 ng/ml ϩ VH group; ‡, p Ͻ 0.05 compared with the pertussis toxin 100 ng/ml ϩ VH group. Results represent five separate experiments with three replicates per treatment group. One of the representative graphs is shown in the inset.
Effect of Zero-Extracellular Calcium Concentration on Cannabinol-Induced Elevation in [Ca
2؉ ] i. In several cell types, thapsigargin is a powerful tool used to determine whether the elevation in [Ca 2ϩ ] i is due to an intracellular store release. However, as demonstrated in Fig. 5C , thapsigargin treatment of resting splenocytes induced a sustained elevation in [Ca 2ϩ ] i , which was likely due to the activation of calcium release-activated calcium channels to subsequently stimulate [Ca 2ϩ ] e influx (Zweifach and Lewis, 1993) . This sustained elevation prohibited the use of thapsigargin to determine directly whether cannabinol-induced elevation of [Ca 2ϩ ] i was due to depletion of intracellular stores. Thus, studies were performed in the presence and absence of extracellular calcium to determine whether the cannabinolinduced elevation in intracellular calcium was due to influx of extracellular calcium. The calcium response induced by cannabinol was drastically reduced when the studies were conducted in the absence of [Ca 2ϩ ] e , indicating the elevation of [Ca 2ϩ ] i by cannabinol occurred primarily via influx of extracellular calcium although a modest increase in [Ca 2ϩ ] i by cannabinol was still observed (Fig. 6A) . Ionomycin-stimulated elevation in [Ca 2ϩ ] i was used to confirm the absence of extracellular calcium in the buffer (Fig. 6B) . As expected for ionomycin, the first phase was primarily due to release of intracellular stores of calcium, which was not affected by the zero-extracellular calcium concentration conditions, and the second phase was due to influx of extracellular calcium, which was abolished under these conditions (Cantrell, 1996) . 2؉ ] i . Induction of [Ca 2ϩ ] i elevation with cannabinoid treatment has been demonstrated in a number of other cell types in a cannabinoid receptor-dependent manner (Sugiura et al., 1999 (Sugiura et al., , 2000 . Cannabinol-induced [Ca 2ϩ ] i elevation in resting splenocytes was mediated primarily via an influx of extracellular calcium, also suggesting a putative role for membrane-bound receptors. In light of these previous findings, SR144528 and SR141716A were used to examine the involvement of CB1 and CB2 in cannabinol-induced elevation of [Ca 2ϩ ] i in resting splenocytes and thymocytes. Studies were conducted in thy- (Schatz et al., 1997) , only the CB2 antagonist SR144528 was used to address the putative role of the CB2 receptor in cannabinol-induced elevation in [Ca 2ϩ ] i in thymocytes. As presented in (Gallichio et al., 1994; Nghiem et al., 1994) . Indeed, pretreatment of splenocytes with ionomycin, over a wide concentration range, for 30 min before activation resulted in a drastic inhibition of interleukin-2 production. This result was confirmed with two other agents that elevate [Ca 2ϩ ] i , A23187, and thapsigargin (Fig.  7) . The concentrations used for both ionomycin and thapsigargin are in the same range as those used in the [Ca 2ϩ ] i determination studies, providing a correlation between the magnitude of [Ca 2ϩ ] i elevation and the magnitude of interleukin-2 inhibition.
Effect of Cannabinoid Receptor Antagonists on Cannabinol-Induced Elevation in [Ca
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In the present study, cannabinoid-mediated inhibition of PMA/Io-stimulated interleukin-2 production in mouse splenocytes was not solely dependent on the presence of CB1 or CB2. The rank order of cannabinoid-induced interleukin-2 inhibition for both potency and efficacy did not correlate with the published K i values for receptor binding. The rank order potency for cannabinoid agonist-induced inhibition of interleukin-2 in PMA/Io-stimulated splenocytes as assessed by IC 50 values was WIN 55212-2 Ϸ cannabidiol Ͼ WIN 55212-3 Ϸ cannabinol. The rank order for efficacy as assessed by the ability of the agonist to produce 100% inhibition of PMA/Ioinduced interleukin-2 at the maximum concentration tested was WIN 55212-2 Ͼ cannabidiol Ͼ WIN 55212-3 Ͼ cannabinol. In splenocytes, the K i for WIN 55212-2 was lower than that for cannabinol (Schatz et al., 1997) . In HL-60 cells, rank order binding activity to the CB2 receptor has been reported to be ⌬ 9 -THC Ϸ cannabinol Ͼ Ͼ cannabidiol (Munro et al., 1993) . In addition, there was a 1000-fold difference in affinity between the WIN stereoisomers in CB2-transfected COS cells (Slipetz et al., 1995) . It has also been reported that cannabinol exhibited a 10-fold higher affinity for the CB2 receptor, the predominant cannabinoid receptor expressed in the immune system (Bouaboula et al., 1993; Galiegue et al., 1995; Schatz et al., 1997) . Indeed, cannabinol exhibits immunomodulating effects (Condie et al., 1996; Herring et al., 1998; Faubert and Kaminski, 2000; Yea et al., 2000) , but, as demonstrated here, so did cannabidiol and WIN 55212-3, both of which exhibit low binding affinity for CB1 and CB2.
In contrast to the data presented here, Buckley et al. (2000) determined that ⌬ 9 -THC-induced inhibition of interleukin-2 in ␣-CD3 plus peritoneal macrophage-stimulated T cells was lost in CB2 receptor knockout mice; however, the experimental design was very different from the one described here. In the present study, cannabinoid-induced in- hibition of interleukin-2 from splenic T cells was measured directly. In the study by Buckley et al. (2000) , activated peritoneal macrophages derived from either wild-type or CB2 receptor knockout mice were treated with vehicle or ⌬ 9 -THC for 4 h. Subsequently, the macrophages were cocultured with a helper T cell hybridoma, which produced interleukin-2 in response to the macrophages plus ␣-CD3. In these studies, the macrophages were used as costimulators for optimal interleukin-2 production because they presumably express the B7 molecule required to bind the costimulatory T cell molecule, CD28 (for review, see Harris and Ronchese, 1999 ). However, the expression level of B7 on the macrophages was not measured in either the wild-type or CB2 receptor knockout mice, nor in response to ⌬ 9 -THC treatment. Furthermore, the helper T cell hybridoma that produced interleukin-2 in response to ␣-CD3 plus peritoneal macrophages was not assayed for cannabinoid receptor expression. These critical issues greatly influence the interpretation of the results. Nevertheless, the authors concluded that the loss of cannabinoidinduced inhibition of interleukin-2 was due to the loss of CB2 in the stimulator macrophages and not through direct effects on the helper T cell hybridoma (Buckley et al., 2000) . Concordant with the aforementioned studies, McCoy et al. (1999) demonstrated that the CB2 antagonist was involved in ⌬ 9 -THC-induced inhibition of antigen processing and presentation. Again, although interleukin-2 production from T cells was used as an endpoint, the effect by ⌬ 9 -THC was exerted on the macrophages used to stimulate the T cells (not the T cells themselves) (McCoy et al., 1999) . Thus, under certain exper- , and thapsigargin (TG) elevate intracellular calcium concentration in resting splenocytes. Splenocytes were loaded with fura-2/AM dye for 30 min at RT in the dark. Cells were harvested and washed three times in Ca 2ϩ -KREB buffer to remove excess Fura-2/AM dye from the buffer. Three milliliters of cells was added to a quartz cuvette, and calcium concentration was determined. Cannabinol (A), ionomycin (B), or thapsigargin (C) was added by glass syringe to the cuvette at either 50 or 300 s and the increase in intracellular calcium concentration was measured for 1,800 s total. Maximum and minimum values were obtained with 0.1% Triton X at 1,600 s and 0.5 mM EGTA at 1,700 s, respectively. Intracellular calcium concentration was calculated from the change in the ratio of bound to free calcium. Results represent at least two separate experiments. VH, vehicle. jpet.aspetjournals.org imental conditions, the CB2 receptor seems to be important for antigen processing and/or presentation in macrophages (McCoy et al., 1999; Buckley et al., 2000) . However, it is important to emphasize that neither of the two experimental designs critically evaluated the role of CB1 and CB2 in the direct effects that cannabinoid treatment exerts on T cells to inhibit interleukin-2. The observation that cannabinoids elevated [Ca 2ϩ ] i in a cannabinoid receptor-dependent manner is consistent with several other studies (Sugiura et al., 1999 (Sugiura et al., , 2000 . Interestingly, in splenocytes, SR141716A provided more effective antagonism than did SR144528, but both cannabinoid receptor antagonists partially attenuated the cannabinol-induced elevation in [Ca 2ϩ ] i . In contrast, in thymocytes, CB2 mediated the cannabinol-induced elevation in [Ca 2ϩ ] i because SR144528 almost completely attenuated the response to cannabinol. Although the exact mechanism responsible for the elevation in [Ca 2ϩ ] i by cannabinoids has not been elucidated, it is tempting to speculate that cannabinoid receptors coupled to G␣ s in lymphocytes to mediate the cannabinoid-induced elevation in [Ca 2ϩ ] i . In fact, the ability of cannabinoid receptors to couple to G␣ s has been suggested, particularly for CB1 (Glass and Felder, 1997; Maneuf and Brotchie, 1997) . Another interesting observation was the gradual rise in [Ca 2ϩ ] i induced by cannabinol. Although it is notable that the calcium determinations in this study represent the mean from many cells at any given time point, rather than for a single cell, the gradual rise in [Ca 2ϩ ] i could be attributed to at least one of two possibilities. One possible explanation is that cannabinol induced only a partial depletion of intracellular stores. Alternatively, a rapid reuptake of intracellular calcium occurred concomitantly with the calcium influx. Additional studies will be required to resolve the specific mechanism.
Although the cannabinoid-induced inhibition of PMA/Iostimulated interleukin-2 was not attenuated by either the CB1 or CB2 antagonists, the cannabinoid receptor antagonists attenuated (both alone and in combination) the cannabinol-induced elevation in [Ca 2ϩ ] i in resting splenocytes. This differential role of the cannabinoid receptors in these two cannabinoid-mediated effects suggests either that the elevation in [Ca 2ϩ ] i did not contribute to the cannabinoidinduced inhibition of PMA/Io-stimulated interleukin-2 or it is one of several contributing factors. The present investigation suggests the latter because cannabinoids as well as agents that elevated [Ca 2ϩ ] i (i.e., ionomycin, A23187, and thapsigargin) inhibited PMA/Io-stimulated interleukin-2 production in splenocytes. In concordance with these observations, T cells become unresponsive (anergic) if they receive an inappropriate or incomplete activation signal. Anergy is a state of unresponsiveness in T cells as characterized by decreased production of interleukin-2, and activator protein-1 and nuclear factor-B DNA binding activity (for review, see Maier and Greene, 1998) . In fact, T cells become anergic, as characterized by Ͼ90% block in the ability to produce interleukin-2, if prematurely stimulated with the calcium ionophore A23187 (Gallichio et al., 1994) . In addition, PMA/Io-induced interleukin-2 reporter gene activity was inhibited in response to an 8-h, 2 M ionomycin pretreatment (Nghiem et al., 1994) . This suggests that a premature elevation in [Ca 2ϩ ] i induces anergy, depending on the time of activation of the calcium signal relative to cellular activation and/or the magnitude of the overall elevation in [Ca 2ϩ ] i . Presently, it is unclear whether the time of generation or magnitude of the calcium signal (or both) contributes to an unresponsive state. Nevertheless, this might explain how the [Ca 2ϩ ] i elevation by cannabinoids contributes to the inhibition of interleukin-2 production in PMA/Io-stimulated splenocytes.
The differential role of the cannabinoid receptors in cannabinoid-induced [Ca 2ϩ ] i and cannabinoid-induced interleukin-2 inhibition in PMA/Io-stimulated splenocytes might be due to the requirement for cellular activation in the studies in which interleukin-2 production was measured. The discrepancy might be associated with the observation that cellular activation modulates cannabinoid receptor expression levels in T cells and B cells (Carayon et al., 1998; Noe et al., 2000) . The ability of cellular stimulation to increase or decrease cannabinoid receptor expression depends on cell type, cell maturity, and activation stimulus. In T cells, CB1 receptor mRNA expression was decreased in response to PMA/Io or ␣-CD3 treatment, suggesting that T cell activation inhibits expression of cannabinoid receptors (Noe et al., 2000) . This explanation is only plausible under the assumption that the cannabinoid effects are not solely mediated via the cannabinoid receptors. Thus, assuming a minimal role of cannabinoid receptors in cannabinoid-induced inhibition of PMA/Io- Fig. 7 . Inhibition of PMA/Io-stimulated interleukin-2 (IL-2) production by ionomycin (Io), A23187, and thapsigargin (TG). Splenocytes were treated with ionomycin, A23187, or thapsigargin followed by activation with PMA/Io (40 nM/0.5 M) for 24 h. For the ionomycin-treated samples, the concentrations of ionomycin are in addition to that given in combination with PMA (i.e., 0.5 M plus the indicated concentrations). Cellular viability was Ն80% for all treatment groups as assessed by trypan blue exclusion. The supernatants were harvested and interleukin-2 production was measured by ELISA analysis. ‫,ء‬ p Ͻ 0.05 compared with the vehicle (VH) group. VH is 0.1% dimethyl sulfoxide. Results represent three separate experiments with three replicates per treatment group. stimulated interleukin-2, the CB1 and/or CB2-dependent component would not be detected in activated cells. A second possible explanation for the discrepancy is that these two responses occurred in distinct cell populations in the splenocyte cell preparation. However, this latter scenario seemed unlikely based on the demonstration that SR144528 attenuated the cannabinol-induced [Ca 2ϩ ] i elevation in thymocytes, a predominantly T cell preparation.
Another interesting observation was that despite the fact that both WIN isomers inhibited interleukin-2 production, there were consistent differences in efficacy especially at concentrations above 10 M, suggesting that the two isomers differentially affected a specific cellular target, as opposed to a nonspecific mechanism of cell perturbation. In addition, the inability of pertussis toxin to attenuate cannabinol-mediated inhibition of PMA/Io-stimulated interleukin-2 suggests that the cannabinoid receptors might couple to G proteins, other than G␣ i /G␣ o . Again, it has been suggested that CB1 might couple to G␣ s (Glass and Felder, 1997; Maneuf and Brotchie, 1997) .
Together, these data support the notion that cannabinoidinduced inhibition of interleukin-2 production is not solely dependent on the presence of CB1 and CB2 in mouse splenocytes. Furthermore, the present results suggest a strong likelihood of multiple parallel mechanisms for the cannabinoid-induced inhibition of interleukin-2 production based on the observation that cannabinol-induced elevation in [Ca 2ϩ ] i was attenuated by the cannabinoid receptor antagonists, whereas the cannabinol-induced inhibition of PMA/Io-stimulated interleukin-2 production was not affected by the antagonists. Collectively, these results point toward the possibility that cannabinoids modulate interleukin-2 expression via a combination of cannabinoid receptor-mediated mechanisms, and CB1/CB2-independent mechanisms.
